prikaz prve stranice dokumenta Učinkovitost i sigurnost ruksolitiniba u liječenju mijelofibroze - iskustvo Zavoda za hematologiju KBC Split
  Download
PDF 1.96 MB
master's thesis
Učinkovitost i sigurnost ruksolitiniba u liječenju mijelofibroze - iskustvo Zavoda za hematologiju KBC Split
2024. urn:nbn:hr:171:012041
Jurinčić, Dora
University of Split
School of Medicine

Cite this document

Jurinčić, D. (2024). Učinkovitost i sigurnost ruksolitiniba u liječenju mijelofibroze - iskustvo Zavoda za hematologiju KBC Split (Master's thesis). Split: University of Split, School of Medicine. Retrieved from https://urn.nsk.hr/urn:nbn:hr:171:012041

Jurinčić, Dora. "Učinkovitost i sigurnost ruksolitiniba u liječenju mijelofibroze - iskustvo Zavoda za hematologiju KBC Split." Master's thesis, University of Split, School of Medicine, 2024. https://urn.nsk.hr/urn:nbn:hr:171:012041

Jurinčić, Dora. "Učinkovitost i sigurnost ruksolitiniba u liječenju mijelofibroze - iskustvo Zavoda za hematologiju KBC Split." Master's thesis, University of Split, School of Medicine, 2024. https://urn.nsk.hr/urn:nbn:hr:171:012041

Jurinčić, D. (2024). 'Učinkovitost i sigurnost ruksolitiniba u liječenju mijelofibroze - iskustvo Zavoda za hematologiju KBC Split', Master's thesis, University of Split, School of Medicine, accessed 17 November 2024, https://urn.nsk.hr/urn:nbn:hr:171:012041

Jurinčić D. Učinkovitost i sigurnost ruksolitiniba u liječenju mijelofibroze - iskustvo Zavoda za hematologiju KBC Split [Master's thesis]. Split: University of Split, School of Medicine; 2024 [cited 2024 November 17] Available at: https://urn.nsk.hr/urn:nbn:hr:171:012041

D. Jurinčić, "Učinkovitost i sigurnost ruksolitiniba u liječenju mijelofibroze - iskustvo Zavoda za hematologiju KBC Split", Master's thesis, University of Split, School of Medicine, Split, 2024. Available at: https://urn.nsk.hr/urn:nbn:hr:171:012041

Please login to the repository to save this object to your list.
Metadata
TitleUčinkovitost i sigurnost ruksolitiniba u liječenju mijelofibroze - iskustvo Zavoda za hematologiju KBC Split
Title (english)Efficacy and safety of ruxolitinib in the treatment of myelofibrosis - experience of the Department of Hematology University Hospital of Split
AuthorDora Jurinčić
MentorDavor Galušić (mentor)
Committee memberDaniela Marasović Krstulović (predsjednik povjerenstva)
Committee memberBenjamin Benzon (član povjerenstva)
Committee memberMarino Vilović (član povjerenstva)
GranterUniversity of Split
School of Medicine
Split
Defense date and country2024-09-17, Croatia
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Internal Medicine
Abstract
Cilj istraživanja: Ispitati učinkovitost i sigurnost ruksolitiniba u liječenju mijelofibroze u stvarnoj kliničkoj praksi. Ispitanici i metode: Provedenim retrospektivnim istraživanjem analizirana je medicinska dokumentacija 52 bolesnika liječenih u Zavodu za hematologiju KBC Split. Kohortu su činili bolesnici s mijelofibrozom u kojih je provedeno liječenje ruksolitinibom. Rezultati: U istraživanje je uključeno 27 bolesnika s dijagnozom primarne i 25 s bolesnika s dijagnozom sekundarne mijelofibroze. Medijan dobi iznosio je 68 godina. Ukupna stopa odgovora na terapiju unutar 6 mjeseci iznosila je 86%, a medijan ukupnog preživljenja kohorte iznosio je 47 mjeseci. Analizirani visokorizični parametri (životna dob >65 godina, hemoglobin <100 g/L, leukocitoza >25 x 10^9/L i prisutnost blasta u perifernoj krvi) povezani su sa statistički značajno lošijim ukupnim preživljenjem bolesnika s mijelofibrozom (P=0,04). Inicijalna masivna splenomegalija nije se pokazala kao loš prognostički prediktor ukupnog preživljenja. Sigurnosni profil ruksolitiniba je prihvatljiv te su najčešće zabilježene nuspojave bile trombocitopenija i anemija. Zaključak: Ruksolitinib je učinkovita terapija u liječenju primarne i sekundarne mijelofibroze. Sigurnosni profil ruksolitiniba je prihvatljiv. Potrebno je dulje praćenje ispitanika čime bi se adekvatnije usporedili rezultati iz stvarne kliničke prakse s rezultatima velikih multicentričnih istraživanja.
Abstract (english)
Objectives: To determine the efficacy and safety of ruxolitinib in the treatment of myelofibrosis in “real life” clinical practice. Participants and methods: The medical documentation of 52 patients treated at the Department of Hematology of KBC Split was analyzed in a retrospective study. The cohort consisted of patients with myelofibrosis who were treated with ruxolitinib. Results: The study included 27 patients with a diagnosis of primary and 25 patients with a diagnosis of secondary myelofibrosis, with a median age of 68 years. The overall response rate in the first six months was 86%, and the median overall survival of the cohort was 47 months. The analyzed high—risk parameters (age >65 years, hemoglobin <100 g/L, leukocytosis >25 x 10^9/L and the presence of blasts in the peripheral blood) were associated with a statistically significantly worse overall survival of patients with myelofibrosis (P=0.04). Initial massive splenomegaly did not appear to be a poor predictor of overall survival. The safety profile of ruxolitinib was acceptable, and the most frequently recorded side effects were thrombocytopenia and anemia. Conclusion: Ruxolitinib is an effective therapy for primary and secondary myelofibrosis. The safety profile of ruxolitinib is acceptable. A longer follow—up of the subjects is needed to more adequately compare the results from real clinical practice with the results of large multicenter studies.
Keywords
Keywords (english)
Languagecroatian
URN:NBNurn:nbn:hr:171:012041
Study programmeTitle: Medicine
Study programme type: university
Study level: integrated undergraduate and graduate
Academic / professional title: doktor/doktorica medicine (doktor/doktorica medicine)
Type of resourceText
File originBorn digital
Access conditionsOpen access
Embargo expiration date: 2024-09-17
Terms of useLicence In copyright icon
Created on2024-09-17 06:22:02